Regulatory exclusivities for pharmaceutical innovation - A panel debate at Harvard Law School

Aktivitet: Tale eller præsentation - typerForedrag og mundtlige bidrag

Timo Minssen - Oplægsholder

The speech will be held on 19 February 2014 during a public panel debate at Harvard Law School where I am guest scholar in 2014 . The event with the title "Patents Without Patents: Regulatory Incentives for Innovation in the Drug Industry" will be hosted by the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics.

More on the topic of the event:

In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs. But patents aren’t the whole story; regulatory agencies also offer different forms of exclusivity—enforced by the agencies themselves—to encourage different forms of innovation in the industry.

The panel will discuss actual and potential roles for those rewards in the context of developing new drugs, new uses for old drugs, and new ways to make drugs, in both the United States and the European Union.

Panelists include:

Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director, the Petrie-Flom Center

W. Nicholson Price II, Academic Fellow, the Petrie-Flom Center

Timo Minssen, Associate Professor, University of Copenhagen Faculty of Law; Visiting Scholar, the Petrie-Flom Center

Moderator, Aaron Kesselheim, Assistant Professor of Medicine, Harvard Medical School; Director of the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital

This event is free and open to the public. Lunch will be served. For questions, contact or 617-495-2316.

Further information is available at:

19 feb. 2014

Begivenhed (Seminar)

TitelPatents without patents: Regulatory Incentives for Innovation in the Drug Industry
AfholdelsesstedHarvard Law School, Wasserstein Hall 1015, 1585 Massachusetts Ave., Cambridge, MA

ID: 96282529